5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl-naphthalen-2-ylamine

ID: ALA475813

Cas Number: 92872-51-0

PubChem CID: 660996

Max Phase: Preclinical

Molecular Formula: C16H13N5

Molecular Weight: 275.31

Molecule Type: Small molecule

Names and Identifiers

Synonyms: TCMDC-125840 | MMV011099 | TCMDC-125840 | 92872-51-0|5-methyl-n-(naphthalen-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine|TCMDC-125840|MMV011099|GW648495|(5-Methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-naphthalen-2-yl-amine|5-methyl-N-naphthalen-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine|Oprea1_485733|MLS000077665|CHEMBL475813|SCHEMBL4935254|JMC521864 Compund DSM1|BDBM24400|HMS2480E04|MFCD01099828|NSC766449|Triazolopyrimidine-Based Compound, 7|AKOS005488471|AKOS030519061|NSC-766449|NCGC0002004Show More⌵

Canonical SMILES:  Cc1cc(Nc2ccc3ccccc3c2)n2ncnc2n1

Standard InChI:  InChI=1S/C16H13N5/c1-11-8-15(21-16(19-11)17-10-18-21)20-14-7-6-12-4-2-3-5-13(12)9-14/h2-10,20H,1H3

Standard InChI Key:  WPVMVODGPNYYEV-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 21 24  0  0  0  0  0  0  0  0999 V2000
   -4.0482    0.2038    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0494   -0.6221    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3358   -1.0341    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3376    0.6159    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6236    0.2074    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6233   -0.6175    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8386   -0.8722    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3539   -0.2046    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8390    0.4625    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3401    1.4394    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7628   -1.0332    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6282    1.8532    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9123    1.4392    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9223    3.0861    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6308    2.6706    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2029    2.6767    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2046    1.8484    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4893    1.4347    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2282    1.8480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2259    2.6794    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4900    3.0894    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  4 10  1  0
  5  6  1  0
  2 11  1  0
 10 12  1  0
  2  3  2  0
 12 13  2  0
 13 17  1  0
  3  6  1  0
 16 14  1  0
  1  2  1  0
 14 15  2  0
 15 12  1  0
  5  4  1  0
  6  7  2  0
 16 17  1  0
  7  8  1  0
 17 18  2  0
  8  9  2  0
 18 19  1  0
  9  5  1  0
 19 20  2  0
  4  1  2  0
 20 21  1  0
 21 16  2  0
M  END

Alternative Forms

1. Parent:

   

   ALA475813

   5-Methyl-n-(naphthalen-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 275.31

Molecular Weight (Monoisotopic): 275.1171

AlogP: 3.33

#Rotatable Bonds: 2

Polar Surface Area: 55.11

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: ┄

CX LogP: 2.86

CX LogD: 2.86

Aromatic Rings: 4

Heavy Atoms: 21

QED Weighted: 0.61

Np Likeness Score: -2.08

References

1. Gujjar R, Marwaha A, El Mazouni F, White J, White KL, Creason S, Shackleford DM, Baldwin J, Charman WN, Buckner FS, Charman S, Rathod PK, Phillips MA..  (2009)  Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice.,  52  (7): [PMID:19296651] [10.1021/jm801343r]

2. Phillips MA, Gujjar R, Malmquist NA, White J, El Mazouni F, Baldwin J, Rathod PK..  (2008)  Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum.,  51  (12): [PMID:18522386] [10.1021/jm8001026]

3. Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL, Vanderwall DE, Green DV, Kumar V, Hasan S, Brown JR, Peishoff CE, Cardon LR, Garcia-Bustos JF..  (2010)  Thousands of chemical starting points for antimalarial lead identification.,  465  (7296): [PMID:20485427] [10.1038/nature09107]

4. PubChem BioAssay data set, 

5. Gujjar R, El Mazouni F, White KL, White J, Creason S, Shackleford DM, Deng X, Charman WN, Bathurst I, Burrows J, Floyd DM, Matthews D, Buckner FS, Charman SA, Phillips MA, Rathod PK..  (2011)  Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.,  54  (11): [PMID:21517059] [10.1021/jm200265b]

6. Simon Macdonald, Paul Willis, Paul Kowalczyk, Thomas Spangenberg, Jeremy Burrows and Tim Wells. Medicines for Malaria Venture (MMV), PO Box 1826, 20, rte de Pré-Bois, 1215 Geneva 15, Switzerland and SCYNEXIS Inc. P.O. Box 12878 Research Triangle Park, North Carolina 27709-2878 USA. Malaria Box,  [10.6019/CHEMBL2028040]

7. Ben Gold, Thulasi Warrier, Selin Somersan, Landys Lopez-Quezada, Julia Roberts, David Little and Carl Nathan.. Malaria Box Tuberculosis Screening Data,  [10.6019/CHEMBL2094260]

8. Bedingfield PT, Cowen D, Acklam P, Cunningham F, Parsons MR, McConkey GA, Fishwick CW, Johnson AP..  (2012)  Factors influencing the specificity of inhibitor binding to the human and malaria parasite dihydroorotate dehydrogenases.,  55  (12): [PMID:22621375] [10.1021/jm300157n]

9. Conor Caffrey and Brian Suzuki; Center for Discovery and Innovation in Parasitic Diseases, Dept. of Pathology, University of California San Francisco (www.cdipd.org).. Malaria Box Schistosomiasis Screening Data,  [10.6019/CHEMBL2363022]

10. Xu M, Zhu J, Diao Y, Zhou H, Ren X, Sun D, Huang J, Han D, Zhao Z, Zhu L, Xu Y, Li H..  (2013)  Novel selective and potent inhibitors of malaria parasite dihydroorotate dehydrogenase: discovery and optimization of dihydrothiophenone derivatives.,  56  (20): [PMID:24073986] [10.1021/jm400938g]

11. UCSF DeRisi Lab. UCSF DeRisi Lab MMV Box Apicoplast Screening,  [10.6019/CHEMBL2448809]

12. University of Vermont. MMV Box Cryptosporidium parvum screening set,  [10.6019/CHEMBL3137356]

13. Northwick Park. MMV Box Onchocerca lienalis screening set,  [10.6019/CHEMBL3137381]

14. Boyom, F.F., Fokou, P.V.T., Tchokouaha, L.R.Y., Spangenberg, T., Mfopa, A.N., Kouipou, R.M.T., Mbouna, C.J., Donkeng Donfack, V.F., Zollo, P.H.A. University of Yaoundé, IMPM Yaoundé and MMV.. MMV Malaria Box screening against Toxoplasma gondii and Entamoeba histolytica.,  [10.6019/CHEMBL3301448]

15. Imperial-Medicines for Malaria Venture Centre of Excellence, Imperial College, London.. MMV Malaria Box gametocyte functional viability assay screening.,  [10.6019/CHEMBL3301451]

16. Medicines for Malaria Venture.. MMV Malaria Box hERG screening.,  [10.6019/CHEMBL3301458]

17. Hui Lab, SGC, University of Toronto, Canada.. MMV Malaria Box thermal shift screening.,  [10.6019/CHEMBL3301461]

18. Igarashi Lab, National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Japan. MMV Malaria Box anti-babesial screening.,  [10.6019/CHEMBL3301464]

19. Kaiser Lab, University Hospital Essen, Germany.. MMV Malaria Box screening against Plasmodium falciparum Deoxyhypusine hydroxylase,  [10.6019/CHEMBL3301470]

20. Ketas, T., Moore, J.P., Weill Cornell Medical College, USA.. MMV Malaria Box HIV and cytotoxicity screening.,  [10.6019/CHEMBL3301472]

21. National Cancer Institute, NIH.. MMV Malaria Box screening against the the NCI60 panel of human tumor cell lines.,  [10.6019/CHEMBL3301486]

22. St Onge, R.P. Yeast Chemical Genomics Laboratory, Stanford Genome Technology Center, Stanford University.. MMV Malaria Box yeast growth screening.,  [10.6019/CHEMBL3301546]

23. Poulsen, S-A., Andrews, K.T., Tonissen, K.F., Nawaratna, S., Eskitis Institute for Drug Discovery, Griffith University, Australia.. MMV Mararia Box screening against P. falciparum asexual stage parasites under hypoxia and bicarbonate modified culture conditions.,  [10.6019/CHEMBL3301550]

24. Taramelli Lab, University of Milan, Italy.. MMV Malaria Box screening in pLDH viability assay against Plasmodium falciparum gametocytes.,  [10.6019/CHEMBL3301555]

25. Van Voorhis Lab, University of Washington, USA.. MMV Box screening against Plasmodium falciparum protein kinases and aminoacyl tRNA synthetases.,  [10.6019/CHEMBL3301562]

26. Horrocks lab, Keele University, UK.. MMV box screening in the Dd2 P. falciparum strain,  [10.6019/CHEMBL3392922]

27. LT Jensen lab, Mahidol University, Thailand (submitted by: Laran T. Jensen, Worathad Chindaudomsate, Amornrat Naranuntarat Jensen). MMV box selection for compounds with potential use in combination with artemisinin using S. cerevisiae,  [10.6019/CHEMBL3392924]

28. Zhu J, Han L, Diao Y, Ren X, Xu M, Xu L, Li S, Li Q, Dong D, Huang J, Liu X, Zhao Z, Wang R, Zhu L, Xu Y, Qian X, Li H..  (2015)  Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase.,  58  (3): [PMID:25580811] [10.1021/jm501127s]

29. TropIQ Health Sciences. MMV Malaria Box gametocyte standard membrane feeding assay screening.,  [10.6019/CHEMBL3430850]

30. St. Jude Leishmania screening dataset.,  [10.6019/CHEMBL3433997]

31. St. Jude Leishmania screening dataset.,  [10.6019/CHEMBL3433997]

32. Singh K, Kaur T.  (2016)  Pyrimidine-based antimalarials: design strategies and antiplasmodial effects,  7  (5): [10.1039/C6MD00084C]

33. Pippione AC, Sainas S, Goyal P, Fritzson I, Cassiano GC, Giraudo A, Giorgis M, Tavella TA, Bagnati R, Rolando B, Caing-Carlsson R, Costa FTM, Andrade CH, Al-Karadaghi S, Boschi D, Friemann R, Lolli ML..  (2019)  Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies.,  163  [PMID:30529545] [10.1016/j.ejmech.2018.11.044]

34. Boschi D, Pippione AC, Sainas S, Lolli ML..  (2019)  Dihydroorotate dehydrogenase inhibitors in anti-infective drug research.,  183  [PMID:31557612] [10.1016/j.ejmech.2019.111681]

35. Oukoloff K, Lucero B, Francisco KR, Brunden KR, Ballatore C..  (2019)  1,2,4-Triazolo[1,5-a]pyrimidines in drug design.,  165  [PMID:30703745] [10.1016/j.ejmech.2019.01.027]

36. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani.  (2020)  Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen,  [10.6019/CHEMBL4495564]

37. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen.  (2020)  Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort,  [10.6019/CHEMBL4495565]

38. Lawong A, Gahalawat S, Okombo J, Striepen J, Yeo T, Mok S, Deni I, Bridgford JL, Niederstrasser H, Zhou A, Posner B, Wittlin S, Gamo FJ, Crespo B, Churchyard A, Baum J, Mittal N, Winzeler E, Laleu B, Palmer MJ, Charman SA, Fidock DA, Ready JM, Phillips MA..  (2021)  Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in Plasmodium falciparum.,  64  (5.0): [PMID:33620219] [10.1021/acs.jmedchem.0c02022]

Source

Source(6):

• Scientific Literature
• GSK Malaria Screening
• PubChem BioAssays
• MMV Malaria Box
• St Jude Leishmania Screening
• SARS-CoV-2 Screening Data 2020-21